RxDoctor Payments Data

Waddah Salman, MD

Interventional Cardiology · Jacksonville, FLNPI 1568441012

Payments from drug & device makers

$6,066in general payments, 2019–2025

Across 268 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Bard Peripheral Vascular, Inc.$874
  • Novartis$860
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$410
  • Merck$314
  • Johnson & Johnson$307
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$3846%
  • Food & beverage$5,45590%
  • Education$2284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,066 in reported general payments places this provider in the 35th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$250,487
Medicare patients
845
Services billed
3,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$48,323
XareltoRivaroxaban22$22,376
EntrestoSacubitril/Valsartan14$14,050
EdarbyclorAzilsartan Med/Chlorthalidone19$4,489
Metoprolol Succinate197$3,263
Rosuvastatin Calcium90$1,366
Amlodipine Besylate192$1,304
Valsartan54$1,254
ClopidogrelClopidogrel Bisulfate99$1,182
Atorvastatin Calcium164$1,099
Nifedipine ErNifedipine38$930
Torsemide27$728
Carvedilol87$681
Midodrine Hcl11$585
Lisinopril76$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$190$48,32354 claims
Johnson & JohnsonXarelto$307$22,37622 claims
NovartisEntresto$860$14,05014 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$102$4,48919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →